HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.17) - GLP-1s Inflection Point, Novartis to Acquire Avidity Biosciences

Pre-IPO Aux Electric Co (PHIP Updates) - Concerns About Business Model and Valuation Outlook

Pre-IPO GenFleet Therapeutics (PHIP Updates) - Some Points Worth the Attention

Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

Pre-IPO TCMTech - The Business Model and the Outlook

Pre-IPO BenQ BM Holding (PHIP Updates) - Some Points Worth the Attention

China Healthcare (Apr.13) - Trump's Tariffs on Pharmaceuticals, NSCEB's Report, RemeGen's Pain Point

Equity Capital Markets

Jiangxi Institute of Biological Products / Equity Capital Markets

Jiangxi Institute of Biological Products (JIBP HK)

<ul>
<li>In the field of Human TAT, Jiangxi Institute of Biological Products (JIBP)  is in a dominant position. Net profit CAGR was much higher than the revenue CAGR, indicating strong profitability.</li>
<li>This market is not big with obvious growth ceiling. Future CAGR of JIBP would gradually slow down if it continues to mainly rely on Human TAT to contribute performance. </li>
<li>Since the technical barriers in Human TAT industry are relatively high, and JIBP is a global leader in this field, JIBP’s valuation can at least reach the industry average level.</li>
</ul>


In the field of Human TAT, Jiangxi Institute of Biological Products (JIBP)  is in a dominant position. Net profit CAGR was much higher than the revenue CAGR, indicating strong profitability.
This market is not big with obvious growth ceiling. Future CAGR of JIBP would gradually slow down if it continues to mainly rely on Human TAT to contribute performance. 
Since the technical barriers in Human TAT industry are relatively high, and JIBP is a global leader in this field, JIBP’s valuation can at least reach the industry average level.


Hualan Biological Engineering (002007 CH)

Jiangxi Boya Bio Pharmaceutical (300294 CH)

Shanghai RAAS Blood Products C (002252 CH)

Pre-IPO Jiangxi Institute of Biological Products-Concerns Behind the Strong Growth and Profitability